Ashvattha Therapeutics, Inc.的动态

2,651 位关注者

2 个月

We are developing a radiopharmaceutical that targets TAM (tumor associate macrophage) without any targeting ligand. Thought that was impossible, think again. Because our radiopharmaceutical is an HDT (hydroxyl dendrimer therapeutic) it comes with minimum toxicity to patients. #oncology #cancer #radiopharm

Transcript

Tumor associated macrophages or Tams are present within a tumour microenvironment. And pose a challenge to cancer drug development, limiting effective treatment with current therapeutics. For these reasons, Tams represent a promising therapeutic target. Ashwathi Therapeutics addresses these challenges with its unique hydroxyl dendrimer HD technology providing precision intracellular targeting to Tams without the requirement for a targeting ligand. HD's are metabolically stable, non-toxic and well tolerated. They are more specific than antibodies and retained in the Tams for up to one month after a single dose. Drugs or radioactive compounds such as radiopharmaceuticals may be conjugated to HDS. After administration of HD, they distribute rapidly throughout the body. HDS only escaped the vasculature in tumours. And are selectively taken up by Tams whilst avoiding healthy cells due to their enhanced phagocytic ability. Uptake by Tams has been demonstrated in a range of cancers. Upon intracellular uptake, the HDS travelled to the lysosome. Four, release into the cytosol. Where they persist for up to one month, enabling prolonged tumoricidal action without systemic side effects. Tams targeted by PHD's act as a depot for radiation, providing a bystander effect. As Tams die, the immune system can recognize the tumour and respond to checkpoint inhibition. HP's not taken up by Tams are cleared by excretion fully intact through the kidneys without causing systemic toxicity. Hydroxyl dendrimers are a unique therapeutic platform. Enabling precision targeting of Tams to effectively treat several oncology indications with the same HD radio pharmaceutical.

要查看或添加评论，请登录

最相关的动态

Innovent Biologics

27,057 位关注者
8 个月
举报此动态
Innovent is presenting clinical data on our first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein (IBI363) at the 2024 ESMO Virtual Plenary, June 13-14. Read below about this antibody's promising safety signals, its broad anti-tumor activity and its applicability across tumor types. #ESMOVirtualPlenary #oncology #InnoventBiologics https://lnkd.in/guaqFQmN
赞评论
要查看或添加评论，请登录
Joseph Ciccolini

Full Professor of Pharmacokinetics, Clinical Pharmacologist, Honey-Maker and Beekeeper
1 个月
举报此动态
Raiders of the Lost Ark: Found it! Found the only presentation in the whole of #ASCO-#GI2025 that pays attention to #PKPD considerations and the impact of #drug #plasma #levels on #efficacy. Thanks to AbbVie for presenting their data on anti-MET-anti-topo1 #Telisotuzumab-#Adizutecan ADC in #metastatic #colorectal #cancer. Mind you, Cavg of the ADC after the first cycle predicts #molecular #response - whereas C-Met expression has no effect on PK, so please don't talk about TMDD and reverse causality!? American Society of Clinical Oncology (ASCO) #pharmacokinetics #ADC #pharmacometrics #oncology
赞评论
要查看或添加评论，请登录
Champions Oncology, Inc.

9,892 位关注者
6 个月
举报此动态
??New Webinar Alert: Join Champions for our upcoming webinar ?? How to Design a Successful 3D Tumor Model Co-Culture Study Thursday September 5th, 2024 4pm CEST ?10am EST ?7am PST Save your spot: https://hubs.li/Q02LJyhH0 Join us for an insightful webinar with our immuno-oncology expert Dr. Mara Gilardi. This session will guide you through different aspects of designing an effective ex vivo 3D tumor model co-culture studies, focusing on model selection, donor choice, optimizing tumor-to-immune cell ratios, selecting controls, and choosing key readouts. Learn how to elevate your research with advanced 3D tumor models for more impactful oncology studies. #ImmunoOncology #tumorgraft3d #organoid #3dtumormodel #exvivo #CancerTreatment #OncologyInnovation #ImmunoTherapeutics #CancerTreatment ##CancerImmunotherapy #organoids #Coculture
赞评论
要查看或添加评论，请登录
American Society for Pharmacology and Experimental Therapeutics - ASPET

4,594 位关注者
3 个月
举报此动态
Researchers from Singapore found abiraterone as a “weak” OATP1B inhibitor (Ki 3.9 μM). Further PBPK simulation and clinical studies showed the absence of OATP1B-mediated DDI between its endogenous biomarker coproporphyrin I and abiraterone in cancer patients. Read more here: https://ow.ly/6lPe50UgSbb #DMD #pharmacology
赞评论
要查看或添加评论，请登录
Ratio Therapeutics

6,774 位关注者
3 个月
举报此动态
Ratio CEO Dr. Jack Hoppin recently spoke with Kyle LaHucik of Endpoints News about Ratio’s collaboration agreement with Novartis, why he is so excited to partner with the Novartis team, and Ratio’s plans for 2025. ? The collaboration leverages Ratio’s radioligand therapy expertise and technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. ? Read here for additional insights into this deal: https://lnkd.in/d-vRK_vK ? #radiotherapeutics #biopharma #news

Novartis strikes radiopharma deal with Ratio worth up to $745M

endpts.com

1 条评论
赞评论
要查看或添加评论，请登录
The Lotus Biotech

7,590 位关注者
8 个月
举报此动态
Prostate cancer is a common concern, but early detection is key! This post explores PSA tests, DRE exams, and what the results might mean for you. Early detection saves lives!? Proactive healthcare is essential. Let's prioritize men's health!? Share this post to raise awareness. https://lnkd.in/gPW6sSiq #ProstateCancer #Cancer #CancerDetection #Oncology #Healthcare #TheLotusBiotech #Pharmaceutical

1 条评论
赞评论
要查看或添加评论，请登录
OncoDaily

39,159 位关注者
2 个月
举报此动态
Overcome PD-1 Resistant in Solid Tumor with a Novel Dual T-cell Agonist approach - Zhen Su, MD MBA https://lnkd.in/dJadC2be Marengo Therapeutics ATP (Apple Tree Partners) ESMO - European Society for Medical Oncology #Cancer #ESMO2024 #Medicine #Health #CancerTreatment #Oncology #OncoDaily
赞评论
要查看或添加评论，请登录
Amos Hedt

Chief Business Strategy Officer at Perspective Therapeutics
10 个月
举报此动态
Lots of interest in this target for both diagnostic imaging and therapeutic applications.
Perspective Therapeutics

8,166 位关注者
10 个月

What is a “Pan-Cancer” Target? Pan is Greek for “all”, meaning a target that works for a range of #cancers. Novel #radiopharmaceutical imaging studies support Fibroblast Activation Protein-α (FAP) as the next promising pan-cancer target. #oncology https://lnkd.in/ePh7Z6Zh
赞评论
要查看或添加评论，请登录
Purple Biotech

1,901 位关注者
3 个月已编辑
举报此动态
We are excited to share the final data from our randomized phase 2 of CM24. The combination of CM24 with nivolumab and Nal-IRI/5FU/LV chemotherapy demonstrates clear and consistent improvement across all efficacy endpoints. Also, a biomarker analysis of serum CEACAM1 and other MoA-related serum markers achieved significant improvement in efficacy parameters positioning CM24 as a treatment for multiple CEACAM1-expressing malignancies. Read the full PR here: https://lnkd.in/e9hhzwGG #PPBT #CEACAM1 #CM24 #pancreaticcancer #biomarker #oncology
赞评论
要查看或添加评论，请登录
Ariceum Therapeutics

4,642 位关注者
4 个月
举报此动态
Are you attending #EANO2024? Meet Austin Smith and CAROL ANDREA PREGONERO GAMEZ, PhD at the 19th Meeting of the EANO European Association of Neuro-Oncology! ?? Austin and Carol will be in Glasgow, UK, from 17-20 October for the congress which aims to bridge gaps in the sector's understanding and management of central nervous system tumours. ?? Get in touch to arrange a meeting with the team to find out more about Ariceum's novel iodine radiolabelled PARP inhibitor #ATT001, which is in clinical development in patients with recurrent #glioblastoma in a first-in-human Phase 1 trial, CITADEL-123. #biotech #radiopharmaceuticals #ATT001 #ATT002 #satoreotide #oncology #cancer #EANO
赞评论
要查看或添加评论，请登录

2,651 位关注者

查看档案关注

登录查看更多内容